Ignite Creation Date:
2024-05-06 @ 1:46 AM
Last Modification Date:
2024-10-26 @ 11:09 AM
Study NCT ID:
NCT01898585
Status:
COMPLETED
Last Update Posted:
2020-01-07
First Post:
2013-07-09
Brief Title:
An Open-Label Study of Zelboraf Vemurafenib in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Single-Arm Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label single-arm multicenter study will assess the safety and efficacy of Zelboraf vemurafenib in patients with Braf V600 mutation positive metastatic melanoma Patients will receive Zelboraf 960 mg twice a day until progressive disease unacceptable toxicity consent withdrawal death reasons deemed by the treating physician or study termination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None